Castello G, D'Alessio V
Servizio di Immunologia Clinica, Istituto Nazionale per lo Studio e la Cura dei Tumori, Napoli.
Clin Ter. 1991 May 15;137(3):155-67.
Innovative approaches to cancer treatment have been made possible today by genetic engineering and hybridoma technologies. In this paper, attention is focused on the use of anti-idiotypic monoclonal antibodies such as internal tumor-associated antigens. These MoAbs may be able to overcome the immunosuppression in cancer patients by stimulating "silent" clones, or by allowing T cell help to become active, thus enhancing the overall immune response which the nominal antigen is unable to do. Preliminary experiences of active specific immunotherapy with monoclonal antiidiotypic antibodies in cancer patients are reported.
如今，基因工程和杂交瘤技术使癌症治疗有了创新方法。本文重点关注抗独特型单克隆抗体作为内部肿瘤相关抗原的应用。这些单克隆抗体或许能够通过刺激“沉默”克隆，或使T细胞辅助变得活跃，从而克服癌症患者的免疫抑制，进而增强名义抗原无法引发的整体免疫反应。本文报告了癌症患者使用单克隆抗独特型抗体进行主动特异性免疫治疗的初步经验。
